This page shows the latest vilaprisan news and features for those working in and with pharma, biotech and healthcare.
Bayer moves vilaprisan into phase III trials for uterine fibroids. ASTEROID study will investigate safety and efficacy of the novel drug. ... Bayer is beginning late-stage trials of vilaprisan, its novel oral, selective progesterone receptor modulator
They include five candidates in phase III trials: copanlisib for non-Hodgkin lymphoma, ODM-201 for hormone-sensitive prostate cancer, finerenone for diabetic kidney disease, vilaprisan for uterine fibroids and endriametosis
Other companies working on new therapies for uterine fibroids include Bayer, which has a candidate called vilaprisan in mid-stage clinical development.
Other companies working on new therapies for uterine fibroids include Bayer, which has a candidate called vilaprisan in mid-stage clinical development.
The other two drugs touted to advance to phase III are copanlisib for non-Hodgkin's lymphoma and vilaprisan to treat symptomatic uterine fibroids – begin tumours that form in the uterus. “
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
Brief us and you’ll soon see we really CAN do it all. We’re different to other agencies. You’ll get expert...